PD-1 monoclonal antibody-activated peripheral blood T-lymphocyte (Tianjin Medical University Cancer Institute and Hospital)

PD-1单抗活化T细胞（天津医科大学）

Report date: 2022/12/17 17:15:39

Base Information

Drug NamePD-1 monoclonal antibody-activated peripheral blood T-lymphocyte (Tianjin Medical University Cancer Institute and Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsLung NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesTianjin Medical UniversityTianjin Medical University Cancer Institute And Hospital
China Registration ClassN/A

Develop Information

Active CompaniesTianjin Medical University Cancer Institute And Hospital
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsLung Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A